

(51) International Patent Classification ⁶ : A61K 47/48		(11) International Publication Number: WO 99/55376			
		(43) International Publication Date: 4 November 1999 (04.11.99)			
(21) International Application Number: PCT/US9 (22) International Filing Date: 28 April 1999 (2)		BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU			
(30) Priority Data: 60/083,340 28 April 1998 (28.04.98) (71) Applicant (for all designated States except US): A RESEARCH SYSTEMS ARS HOLDING N.V. [I John B. Gorsiraweg 14, Curacao (AN).	PPLIE NL/NL	Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.			
(72) Inventors; and (75) Inventors/Applicants (for US only): EL TAYAR [CH/US]; 143 Gerald Road, Milton, MA 0218 ZHAO, Xuan [CN/US]; 2805 Southhust Drive, Hi AL 35803 (US), BENTLEY, Michael, D. [US/US/US/US/US/US/US/US/US/US/US/US/US/U	36 (US untsvill). e,			
(74) Agent: YUN, Allen. C.; Browdy and Neimark, P.L.L. 300, 419 Seventh Street N.W., Washington, DC 200					

(57) Abstract

PEG-LHRH analog conjugates, where a PEG moiety is covalently bound to a serine residue of a LHRH analog either directly or via a bifunctional linker molecule, such as an amino acid, and methods for producing these conjugates are provided in the present invention. Also provided are a pharmaceutical composition and a method for treating pathologies in which LHRH analog administration is beneficial.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia	
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia	
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal	
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland	
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad	
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo	
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan	
BE	Belgium	GN	Guinea	MK	The former Yugoslav	TM	Turkmenistan	
BF	Burkina Faso	GR	Greece		Republic of Macedonia	TR	Turkey	
BG	Bulgaria	HU	Hungary	ML	Mali	TT	Trinidad and Tobago	
BJ	Benin	HE	Ircland	MN	Mongolia	UA	Ukraine	
BR	Brazil	IL	Israel	MR	Mauritania	UG	Uganda	
BY	Belarus	IS	Iceland	MW	Malawi	US	United States of America	
CA	Canada	IT	Italy	MX	Mexico	UZ	Uzbekistan	
CF	Central African Republic	JP	Japan	NE	Niger	VN	Vict Nam	
CG	Congo	KE	Kenya	NL	Netherlands	YU	Yugoslavia	
CH	Switzerland	KG	Kyrgyzstan	NO	Norway	zw	Zimbabwe	
CI	Côte d'Ivoire	KP	Democratic People's	NZ	New Zealand			
CM	Cameroon		Republic of Korea	PL	Poland			
CN	China	KR	Republic of Korea	PT	Portugal			
CU	Cuba	KZ	Kazakstan	RO	Romania			
CZ	Czech Republic	LC	Saint Lucia	RU	Russian Federation			
DE	Germany	LI	Liechtenstein	SD	Sudan			
DK	Denmark	LK	Sri Lanka	SE	Sweden			
EE	Estonia	LR	Liberia	SG	Singapore			

PEG-LHRH ANALOG CONJUGATES

CROSS REFERENCE TO RELATED APPLICATION

The present application claims the benefit of U.S. provisional application no. 60/083,340, filed April 28, 1998, 5 the entire contents of which are herein incorporated by reference.

FIELD OF THE INVENTION

The present invention relates to PEG-LHRH analog conjugates wherein the PEG unit is covalently bound to Ser' 10 either directly or via a bifunctional linker molecule, such as an amino acid. The process for their production as well as their use in the therapy, prognosis or diagnosis of the diseases, in which LHRH analogs' administration is advisable, are further objects of the present invention.

BACKGROUND OF THE INVENTION

Covalent attachment of the hydrophilic polymer polyethylene glycol, (PEG), also known as polyethylene oxide, (PEO), to molecules has important applications in biotechnology and medicine. In its most common form, PEG is a linear polymer 20 having hydroxyl groups at each terminus:

HO-CH2-CH2O (CH2CH2O) CH2CH2-OH

This formula can be represented in brief as HO-PEG-OH, where it is meant that -PEG- represents the polymer backbone without the terminal groups:

25 "-PEG-" means "-CH2CH2O(CH2CH2O) CH2CH2-"

PEG is commonly used as methoxy-PEG-OH, (m-PEG), in which one terminus is the relatively inert methoxy group, while the other terminus is a hydroxyl group that is subject to chemical modification.

30 CH₃O- (CH₂CH₂O) p-CH₂CH₂-OH

15

Branched PEGs are also in common use. The branched PEGs can be represented as $R(-PEG-OH)_a$ in which R represents a central core moiety such as pentaerythritol or glycerol, and m represents the number of branching arms. The number of

35 branching arms (m) can range from three to a hundred or more.

The hydroxyl groups are subject to chemical modification.

PCT/US99/09160 WO 99/55376

Another branched form, such as that described in PCT patent application WO 96/21469, has a single terminus that is subject to chemical modification. This type of PEG can be represented as (CH₃O-PEG-)_pR-X, whereby p equals 2 or 3, R 5 represents a central core such as lysine or glycerol, and X represents a functional group such as carboxyl that is subject to chemical activation. Yet another branched form, the "pendant PEG", has reactive groups, such as carboxyl, along the PEG backbone rather than at the end of PEG chains.

In addition to these forms of PEG, the polymer can 10 also be prepared with weak or degradable linkages in the backbone. For example, Harris has shown in U.S. Patent Application 06/026,716 that PEG can be prepared with ester linkages in the polymer backbone that are subject to hydrolysis. 15 This hydrolysis results in cleavage of the polymer into fragments of lower molecular weight, according to the above

reaction scheme:

-PEG-CO2-PEG- + H2O → -PEG-CO2H + HO-PEG-

As used herein, the term polyethylene glycol or PEG is 20 meant to include all the above described derivatives.

The copolymers of ethylene oxide and propylene oxide are closely related to PEG in their chemistry, and they can be used instead of PEG in many of its applications. They have the following general formula:

HO-CH2CHRO (CH2CHRO) "CH2CHR-OH 25

wherein R is H or CH3.

PEG is a useful polymer having the property of high water solubility as well as high solubility in many organic solvents. PEG is also non-toxic and non-immunogenic. When PEG 30 is chemically attached (PEGylation) to a water insoluble compound, the resulting conjugate generally is water soluble as well as soluble in many organic solvents.

Luteinizing hormone releasing hormone (LHRH or GnRH) is a decapeptide secreted by the hypothalamus and capable of 35 inducing the release of both LH and FSH. It has the following $\label{eq:formula:pyroGlu-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH_2.}$ LHRH can either stimulate pituitary gonadotropin

secretion or be a potent inhibitor. When administered in a

precise pulsatile pattern, LHRH can restore the normal cyclic gonadotropin secretion. Pulsatile administration of LHRH using a computerized pump was used with good results in the induction of ovulation in anovulatory women with hypothalamic dysfunction. 5 When administered chronically, LHRH or its agonists proved to be potent inhibitors of gonadotropic secretion, providing a temporary (fully reversible) gonadotropin specific medical

To date, thousands of LHRH analogs have been
10 synthesized that can act either as agonists or antagonists. In
order to produce LHRH antagonists, which work by receptor
occupancy, it is necessary to substitute several amino acids on
the LHRH molecule. Antagonists also require precise topological
features to achieve high binding affinity to the receptor.

hypophisectomy.

- 15 There are many recently synthesized LHRH analogs in which the amino acids contain aromatic or other functional groups capable of the so-called hydrotropic interaction. The use of LHRH antagonists with their immediate inhibition of gonadotrophin release may be useful in therapeutic areas, such as
- 20 contraception and in treatment of hormone-dependent disorders. In the case of hormone-dependent tumors, avoiding the initial stimulatory phase produced by LHRH agonists may be a particular advantage. For a review on LHRH analogs, see Karten and Rivier, 1986.
- 25 Antide, in particular, is a potent LHRH antagonist, with formula, biological activity and preparation as described in EP Patent 377,665 and reported here below.

ANTIDE

[Acetyl-D-3-(2'-Naphthyl)-alanine)1, D-(4-Chlorophenyl)alanine2, D-3-(3'-Pyridyl)-alanine3, Lysine(NE-Nicotinoyl)5, D-Lysine (NE-Nicotinoyl)6, Lysine (NE-Isopropyl)8, D-Alanine10]-Gonadotropin Releasing Hormone (GnRH)

From studies carried out by the present inventors, it

was found, for example, that antide has a very poor solubility in 0.9% NaCl solution (solubility 25 μ g/ml) or other isotonic 10 media such as phosphate buffered saline (solubility was 16 $\mu q/ml$). Previous formulations of antide (e.g., antide 1 mg/ml

in 5% glucose) have shown poor bioavailability and

pharmacokinetic reproducibility.

5

Covalent attachment of PEG to peptides is a 15 potentially useful approach for delivering water insoluble peptide drugs as shown by Felix (A.M. Felix in J.M. Harris and S. Zalipsky, Eds., Poly(ethylene glycol) Chemistry and Biological Applications, A.C.S Symposium Series 680, pp 218-238, A.C.S. Washington, DC, 1997).

JP patent application JP 3148298 describes peptides-20 (e.g., including GnRH) PEG conjugates obtained by reacting the guanidino group, present for example in the arginine residue, with PEG, while protecting the amino groups present in the molecules.

Citation of any document herein is not intended as an 25 admission that such document is pertinent prior art, or considered material to the patentability of any claim of the present application. Any statement as to content or a date of any document is based on the information available to applicants 30 at the time of filing and does not constitute an admission as to the correctness of such a statement.

SUMMARY OF THE INVENTION

This invention provides novel PEG-LHRH analogs conjugates wherein a PEG unit is covalently bound to Ser either 35 directly or via a bifunctional linker molecule, such as an amino acid. PEG or PEG-linker molecule is bonded, specifically, to the alcohol function of the serine residue. The linkage between

the LHRH analog and the polyethylene glycol or the PEG-linker molecule in these conjugates is subject to hydrolysis at physiological pH (7.2-7.4) and is preferably also subject to hydrolysis by esterases present in the blood.

BRIEF DESCRIPTION OF THE DRAWINGS

5

15

Figure 1 shows a reaction scheme for preparing a PEGantide conjugate with a glycine linker inserted between the PEG and the antide moieties.

Figure 2 shows the Capillary Electrophoresis (CE)

10 graphs of hydrolysis of the PEG-antide conjugate at 37°C in phosphate buffer pH 7.2 at t=0, 460 and 1395 minutes.

Figure 3 shows the hydrolysis kinetics plot deduced from the data of Figure 2 assuming a pseudo first-order kinetics.

DETAILED DESCRIPTION OF THE INVENTION

The conjugates of the present invention, preferably, show a solubility in water of at least 30 mg/ml at room temperature and physiological pH (7.2-7.4) and a solubility in a physiological saline solution of at least 10 mg/ml at the same 20 conditions.

In the case in which the LHRH analog is antide, for example, such properties enable the use of antide as a drug whereas, previously, development of antide as a drug has been rendered difficult due to its poor water solubility.

25 The term "LHRH-analogs", as used herein, is meant to include any decapeptide which is an LHRH agonist or antagonist. Preferably the LHRH analog is an LHRH antagonist; more preferably it is antide.

The conjugates of the present invention can be
30 prepared by any of the methods known in the art. According to
an embodiment of the invention, the LHRH analog is reacted with
a PEGylating agent in a suitable solvent and the desired
conjugate is isolated and purified, for example, by applying one
or more chromatographic methods.

"Chromatographic methods" means any technique that is used to separate the components of a mixture by their application on a support (stationary phase) through which a solvent (mobile phase) flows. The separation principles of the 5 chromatography are based on the different physical nature of stationary and mobile phase.

Some particular types of chromatographic methods, which are well-known in the literature, include: liquid, high pressure liquid, ion exchange, absorption, affinity, partition, 10 hydrophobic, reversed phase, gel filtration, ultrafiltration or thin-layer chromatography.

The "PEGylating agent" as used in the present application means any PEG derivative, which is capable of reacting with the OH of a serine residue or a functional group 15 of a bifunctional linker molecule, such as the amino group of an amino acid linker molecule. The other functional group of the linker molecule serves to form a covalent linkage to the serine

residue of a LHRH analog, i.e., the carboxyl group of an amino acid linker molecule forms an ester linkage with serine. It can 20 be an alkylating reagent, such as PEG aldehyde, PEG epoxide or PEG tresylate, or it can be an acylating reagent, such as PEG-O-(CH₂)_nCO₂-Z where n=1-3 and Z is N-succinimidyl or other suitable activating group.

The PEGylating agent is used in its mono-methoxylated 25 form where only one terminus is available for conjugation, or in a bifunctional form where both termini are available for conjugation, such as for example in forming a conjugate with two LHRR analogs covalently attached to a single PEG moiety. It has a molecular weight between 500 and 100,000, preferably between 30 about 5,000 and 40,000 (40kDa) and more preferably between about 10kDa and 40kDa and most preferably between about 20kDa and

If the PEGylating agent is an acylating agent, it can contain either a norleucine or ornithine residue bound to the 35 PEG unit via an amide linkage. These residues allow a precise determination of the linked PEG units per mole of peptide (see for example Sartore et al., 1991).

40kDa.

A solvent for the PEGylation reaction is preferably a polar aprotic solvent, such as DMF, DMSO, pyridine, etc.

When the LHRH analog is reacted with the PEGylating agent, derivatization can occur on the OH of the Ser moiety, as well as on the amine nitrogen of other residues, such as, for example, on the e-amino group of lysine (in case of antide, on

- 5 N-Isopropyl-Lys*). In such reactions, high selectivity for amine PEGylation can occur. Products formed by PEGylation on amines are amides and while PEG amides can be water soluble, the amide linkage can be stable under physiological conditions, and thus the LHRH analog could not be substantially hydrolytically
- 10 released in vivo. Therefore, using this method, the PEG-LHRH analog ester should be separated from the PEG-LHRH analog amide using chromatography. A limitation of this method is, therefore, low yield of the desired PEG-LHRH analog conjugate.

Therefore, in a preferred embodiment, the LHRH analog 15 is protected on the amine groups which could either react with the PEGylating agent or with a bifunctional linker molecule prior to PEGylation.

In the case of antide, it is therefore preferable to reversibly protect the N-Isopropyl-Lys⁸ residue with a group 20 that can be removed using photochemical, mild hydrolytic, or hydrogenation methods. With the nitrogen thus protected, the hydroxyl group on the serine residue is reacted with a PEGylating reagent to form a PEG ester and the protecting group on the N-Isopropyl-Lys⁸ is then removed to yield antide

- 25 selectively PEGylated on the hydroxyl of the serine residue by an ester linkage. The conditions for removal of the amine protecting group must be sufficiently mild to avoid cleavage of the PEG-antide ester linkage. In another embodiment where a bifunctional linker or spacer molecule is used to link a PEG
- 30 moiety to an LHRH analog such as antide, the protecting group is preferably removed after a bifunctional linker molecule is covalently bound to the serine residue of an LHRH analog or can be removed after PEGylation of the bifunctional linker molecule covalently bound to the LHRH analog.
- 35 Preferred reagents for protection include benzyloxycarbonyl chloride or ring-substituted derivatives of this compound, N-hydroxysuccinimidyl or 1-benzotriazolyl esters of benzyloxycarbonic acid or ring substituted derivatives of tbutoxycarbonyl chloride or the N-hydroxysuccinimidyl or 1-
- 40 benzotriazolyl esters of t-butoxycarbonic acid.

In another embodiment of the invention, the conjugates of the invention can be prepared by using an appropriate PEGylated serine such as Fmoc-Ser(PEG)-OH or tBoc-Ser(PEG)-OH instead of serine during the solid-phase synthesis of the LHRH 5 analogs. An example of Fmoc-Ser(PEG)-OH derivative is shown below.

Fmoc-Ser (PEG)-OH

A regulation of the rate of release in vivo of the LHRH analog can be accomplished by varying n and R in the PEG 10 linkage. In general, as n increases, the rate of release of the LHRH analog decreases and if R is alkyl, the rate of release of the LHRH analog is lower than the rate of release if R is H. In general, as the size of R increases, the rate of release of the LHRH analog, or antide in particular, decreases. Variation 15 of n and R thus provides substantially precise control of the delivery rate in vivo of antide when used as a drug.

According to recent studies, such as U.S. Patent 5,840,900, higher molecular weight PEG appear to be important for obtaining therapeutic efficacy in certain cases. For 20 antide, three PEG-antide conjugates with PEGylating agents having molecular weights of 20kDa or 40kDa have been prepared by modifying the protection-deprotection procedure. In a preferred

embodiment, the PEGylation rate of antide, particularly with higher molecular weight PEG moieties, is increased by first attaching a linker molecule, such as glycine, to the antide and then PEGylating the linker molecule covalently attached to the antide. The reaction scheme for preparing a PEGylated antide with a glycine linker is shown in Figure 1. The scheme in Figure 1 can be used for preparing, for example, conjugates such as PEG2-glycine-antide 20k (a branched 20kDa PEG can be used), mPEG-glycine-antide (a linear 20kDa mPEG can be used), and PEG2-10 glycine-antide 40k (a branched 40kDa PEG can be used). It will be appreciated by those of skill in the art that the scheme

glycine-antide 40k (a branched 40kDa PEG can be used). It will be appreciated by those of skill in the art that the scheme shown in Figure 1 is not limited to antide or glycine linker but can be applied to other LHRH analogs and linker molecules.

The linker molecule is preferably a small bifunctional

The linker molecule is preferably a small bluncetonal
15 molecule, which can rapidly react with the OH group on a serine
residue of a LHRH analog. This linker molecule is preferably a
heterobifunctional linker molecule, such as an amino acid, which
forms an ester with a serine residue of a LHRH analog. The
second functional group of the linker molecule serve as the site
20 for PEGylation by the PEGylating agent. The amino acid,

o for resystation by the resystating agent. The amino actu, glycine, is a preferred heterobifunctional linker molecule according to the present invention. Other suitable linker molecules can be readily recognized or determined by those of skill in the art.

Another object of the present invention is to provide the conjugates in substantially purified form in order for them to be suitable for use in pharmaceutical compositions, as active ingredient for the treatment, diagnosis or prognosis of pathologies in which LHRH analogs' administration is advisable. 30 Such pharmaceutical compositions represent a further object if the present invention.

If the LHRH analog is antide, the above-mentioned pathologies include endometriosis, uterine fibroids, hormonal-dependent cancers (prostate, breast), uterine myoma, LH surge in women undergoing in-vitro fertilization and all the other pathological states reported in EP 377,665.

Further embodiments and advantages of the invention will be evident in the following description.

An embodiment of the invention is the administration 40 of a pharmacologically active amount of the conjugates of the

invention to subjects at risk of developing one of the diseases reported above or to subjects already showing such pathologies.

Any route of administration compatible with the active principle can be used. The preferred is parenteral 5 administration, such as subcutaneous, intramuscular or intravenous injection. The dose of the active ingredient to be administered depends on the basis of the medical prescriptions according to age, weight and the individual response of the patient.

The daily non-weighted dosage for the patient can be between 0.2 to 20 mg, and the preferable daily dose is between 0.2 to 10 mg.

The pharmaceutical composition for parenteral administration can be prepared in an injectable form comprising 15 the active principle and a suitable vehicle. Vehicles for the parenteral administration are well known in the art and comprise, for example, water, saline solution, Ringer solution and/or dextrose.

The vehicle can contain small amounts of excipients 20 in order to maintain the stability and isotonicity of the pharmaceutical preparation.

The preparation of the cited solutions can be carried out according to the ordinary modalities.

The present invention has been described with 25 reference to the specific embodiments, but the content of the description comprises all modifications and substitutions which can be brought by a person skilled in the art without extending beyond the meaning and purpose of the claims.

The invention will now be described by means of the 30 following Examples, which should not be construed as in any way limiting the present invention.

EXAMPLE 1:

10

Preparation of PEG-antide Conjugate

Antide (10 mg, 6.3 mmole) was dissolved in 15 ml of 35 anhydrous pyridine and the resulting solution was azeotropically distilled under vacuum at 45 °C until about 8 ml of pyridine remained. After cooling the solution to room temperature, the succinimidyl ester of carboxymethylated mPEG (93 mg, 19 mmole,

Shearwater Polymers, Huntsville, AL) was added and the solution was stirred for 48 hours under nitrogen at room temperature. The pyridine was then removed under vacuum and products were collected by vacuum filtration after precipitation in ether (50 5 ml), and dried in vacuo.

The product (50 mg) obtained from the previous step was dissolved in deionized water (1.5 ml), and the mixture was filtered through a 0.2 ml syringe filter. The solution was loaded onto an ion exchange chromatography column (CM Sepharose 10 Fast Flow, Pharmacia, Uppsala, Sweden). Eluents were deionized water and 50 mM NaCl solution with a gradient from zero to 60% salt solution. Three peaks were observed, with the middle peak being the desired PEG-antide conjugate, in which the PEG chain is bound to Ser*.

This conjugate was collected by fractionation and freeze-dried. The product was shown to be highly water soluble (>30 mg/ml).

Hydrolysis Kinetics of the PEG-antide conjugate

The hydrolysis of the conjugate was determined using 20 capillary electrophoresis (CE). The calculated half life under these conditions is 5.5 hours as illustrated in Figures 2 and 3.

Having now fully described this invention, it will be appreciated that by those skilled in the art that the same can be performed within a wide range of equivalent parameters,

25 concentrations, and conditions without departing from the spirit and scope of the invention and without undue experimentation.

While this invention has been described in connection with specific embodiments thereof, it will be understood that it is capable of further modifications. This application is

30 intended to cover any variations, uses, or adaptations of the inventions following, in general, the principles of the invention and including such departures from the present disclosure as come within known or customary practice within the art to which the invention pertains and as may be applied to the

35 essential features hereinbefore set forth as follows in the scope of the appended claims.

All references cited herein, including journal articles or abstracts, published or unpublished U.S. or foreign patent applications, issued U.S. or foreign patents, or any 40 other references, are entirely incorporated by reference herein,

including all data, tables, figures, and text presented in the cited references. Additionally, the entire contents of the references cited within the references cited herein are also entirely incorporated by reference.

Reference to known method steps, conventional method steps, known methods or conventional methods is not in any way an admission that any aspect, description or embodiment of the present invention is disclosed, taught or suggested in the relevant art.

The foregoing description of the specific embodiments will so fully reveal the general nature of the invention that others can, by applying knowledge within the skill of the art (including the contents of the references cited herein), readily modify and/or adapt for various applications such specific

15 embodiments, without undue experimentation, without departing from the general concept of the present invention. Therefore, such adaptations and modifications are intended to be within the meaning and range of equivalents of the disclosed embodiments, based on the teaching and guidance presented herein. It is to

20 be understood that the phraseology or terminology herein is for the purpose of description and not of limitation, such that the terminology or phraseology of the present specification is to be interpreted by the skilled artisan in light of the teachings and guidance presented herein, in combination with the knowledge of

25 one of ordinary skill in the art.

WHAT IS CLAIMED IS:

1. A polyethylene glycol-luteinizing hormone releasing hormone (LHRH) analog conjugate having a polyethylene glycol (PEG) moiety covalently bound to a serine residue of LHRH analog, wherein said conjugate is capable of hydrolysis to release said LHRH analog.

- The PEG-LHRH analog conjugate according to claim
 wherein said PEG moiety is covalently bound to said serine
 residue of LHRH analog via a bifunctional linker molecule.
- The PEG-LHRH analog conjugate according to claim
 wherein said bifunctional linker molecule is a heterobifunctional linker molecule.
- 4. The PEG-LHRH analog conjugate according to claim 3, wherein said bifunctional linker molecule forms an ester with said serime residue of LHRH analog.
- The PEG-LHRH analog conjugate according to claim
 wherein said heterobifunctional linker molecule is an amino acid.
- 6. The PEG-LHRH analog conjugate according to claims 5, wherein said heterobifunctional linker molecule is glycine.
- 7. The PEG-LHRH analog conjugate according to any one of claims 1-6, wherein said LHRH analog is a LHRH agonist.
- 8. The PEG-LHRH analog conjugate according to any one of claims 1-6, wherein said LHRH analog is a LHRH antagonist.
- 9. The PEG-LHRH analog conjugate according to claim δ , wherein said LHRH antagonist is antide.
- 10. A process for producing the PEG-LHRH analog conjugate of claim 2, comprising the steps of:

protecting a LHRH analog with a protecting agent to prevent undesirable reactions at residues other than serine;

reacting the protected LHRH analog with a bifunctional linker molecule to covalently attach the bifunctional linker molecule to a serine residue of the protected LHRH analog;

deprotecting the protected LHRH analog;

reacting the deprotected LHRH analog with a PEGylating reagent to attach a PEG moiety to the LHRH moiety via the bifunctional linker molecule covalently bound to the serine residue of LHRH analog; and

recovering the produced PEG-LHRH analog conjugate.

11. A process for producing the PEG-LHRH analog conjugate of claim 1, comprising the steps of:

reacting a LHRH analog with a PEGylating agent to covalently attach a PEG moiety to a serine residue of the LHRH analog to produce a PEG-LHRH analog conjugate; and

recovering the produced PEG-LHRH analog conjugate.

- 12. The process according to claim 11, wherein the PEGylating agent is succinimidyl ester of carboxymethylated monomethoxy PEG.
- 13. The process according to claim 11, further comprising a step of protecting amine groups on the LHRH analog before the PEGylating step.
- 14. The process according to any one of claims 10-13, wherein the PEGylating agent is mono-methoxylated.
- 15. The process according to any one of claims 10-13, wherein the PEGylating agent is bifunctional.
- 16. A process for producing the PEG-LHRH analog conjugate of claim 1, comprising the steps of:

producing a PEG-LHRH analog conjugate by solid phase peptide synthesis, wherein a PEGylated serine residue is introduced into the LHRH analog during solid phase peptide synthesis; and

- recovering the produced PEG-LHRH analog conjugate.
- 17. The process according to claim 16, wherein the PEGylated serine residue is Fmoc-Ser(PEG)-OH or tBoc-Ser(PEG)-OH.
- 18. A pharmaceutical composition, comprising a PEG-LHRH analog conjugate according to any one of claims 1-6 as an active ingredient and a pharmaceutically acceptable carrier, excipient or auxiliary agent.
- 19. A method for treating pathologies in which LHRH analog administration is beneficial, comprising administering an effective amount of the pharmaceutical composition according to claim 12 to a subject in need thereof.
- 20. The use, in the manufacture of a medicament, of the PEG-LHRH analog conjugate of any one of claims 1-6, as an active ingredient.

FIG. 1




FIG. 2




FIG. 3